237 related articles for article (PubMed ID: 24464755)
1. Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.
Barefield D; Kumar M; de Tombe PP; Sadayappan S
Am J Physiol Heart Circ Physiol; 2014 Mar; 306(6):H807-15. PubMed ID: 24464755
[TBL] [Abstract][Full Text] [Related]
2. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice.
Barefield D; Kumar M; Gorham J; Seidman JG; Seidman CE; de Tombe PP; Sadayappan S
J Mol Cell Cardiol; 2015 Feb; 79():234-43. PubMed ID: 25463273
[TBL] [Abstract][Full Text] [Related]
3. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.
Fraysse B; Weinberger F; Bardswell SC; Cuello F; Vignier N; Geertz B; Starbatty J; Krämer E; Coirault C; Eschenhagen T; Kentish JC; Avkiran M; Carrier L
J Mol Cell Cardiol; 2012 Jun; 52(6):1299-307. PubMed ID: 22465693
[TBL] [Abstract][Full Text] [Related]
4. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.
van Dijk SJ; Paalberends ER; Najafi A; Michels M; Sadayappan S; Carrier L; Boontje NM; Kuster DW; van Slegtenhorst M; Dooijes D; dos Remedios C; ten Cate FJ; Stienen GJ; van der Velden J
Circ Heart Fail; 2012 Jan; 5(1):36-46. PubMed ID: 22178992
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
[TBL] [Abstract][Full Text] [Related]
6. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
Kuster DWD; Lynch TL; Barefield DY; Sivaguru M; Kuffel G; Zilliox MJ; Lee KH; Craig R; Namakkal-Soorappan R; Sadayappan S
Cardiovasc Res; 2019 Dec; 115(14):1986-1997. PubMed ID: 31050699
[TBL] [Abstract][Full Text] [Related]
7. MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy.
O'Leary TS; Snyder J; Sadayappan S; Day SM; Previs MJ
J Mol Cell Cardiol; 2019 Feb; 127():165-173. PubMed ID: 30550750
[TBL] [Abstract][Full Text] [Related]
8. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction.
van Dijk SJ; Dooijes D; dos Remedios C; Michels M; Lamers JM; Winegrad S; Schlossarek S; Carrier L; ten Cate FJ; Stienen GJ; van der Velden J
Circulation; 2009 Mar; 119(11):1473-83. PubMed ID: 19273718
[TBL] [Abstract][Full Text] [Related]
9. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations.
Sequeira V; Wijnker PJ; Nijenkamp LL; Kuster DW; Najafi A; Witjas-Paalberends ER; Regan JA; Boontje N; Ten Cate FJ; Germans T; Carrier L; Sadayappan S; van Slegtenhorst MA; Zaremba R; Foster DB; Murphy AM; Poggesi C; Dos Remedios C; Stienen GJ; Ho CY; Michels M; van der Velden J
Circ Res; 2013 May; 112(11):1491-505. PubMed ID: 23508784
[TBL] [Abstract][Full Text] [Related]
10. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
[TBL] [Abstract][Full Text] [Related]
11. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
[TBL] [Abstract][Full Text] [Related]
12. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy.
Parbhudayal RY; Garra AR; Götte MJW; Michels M; Pei J; Harakalova M; Asselbergs FW; van Rossum AC; van der Velden J; Kuster DWD
J Mol Cell Cardiol; 2018 Oct; 123():59-63. PubMed ID: 30170119
[TBL] [Abstract][Full Text] [Related]
13. Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice.
Najafi A; Schlossarek S; van Deel ED; van den Heuvel N; Güçlü A; Goebel M; Kuster DW; Carrier L; van der Velden J
Pflugers Arch; 2015 Jun; 467(6):1303-17. PubMed ID: 25010737
[TBL] [Abstract][Full Text] [Related]
14. A hypertrophic cardiomyopathy-associated MYBPC3 mutation common in populations of South Asian descent causes contractile dysfunction.
Kuster DW; Govindan S; Springer TI; Martin JL; Finley NL; Sadayappan S
J Biol Chem; 2015 Feb; 290(9):5855-67. PubMed ID: 25583989
[TBL] [Abstract][Full Text] [Related]
15. Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy.
Helms AS; Davis FM; Coleman D; Bartolone SN; Glazier AA; Pagani F; Yob JM; Sadayappan S; Pedersen E; Lyons R; Westfall MV; Jones R; Russell MW; Day SM
Circ Cardiovasc Genet; 2014 Aug; 7(4):434-43. PubMed ID: 25031304
[TBL] [Abstract][Full Text] [Related]
16. Characterization of heterozygous and homozygous mouse models with the most common hypertrophic cardiomyopathy mutation MYBPC3
Hilderink S; Schuldt M; Goebel M; Jansen VJ; Manders E; Moorman S; Dorsch LM; van Steenbeek FG; van der Velden J; Kuster DWD
J Mol Cell Cardiol; 2023 Dec; 185():65-76. PubMed ID: 37844837
[TBL] [Abstract][Full Text] [Related]
17. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations.
Witjas-Paalberends ER; Güçlü A; Germans T; Knaapen P; Harms HJ; Vermeer AM; Christiaans I; Wilde AA; Dos Remedios C; Lammertsma AA; van Rossum AC; Stienen GJ; van Slegtenhorst M; Schinkel AF; Michels M; Ho CY; Poggesi C; van der Velden J
Cardiovasc Res; 2014 Jul; 103(2):248-57. PubMed ID: 24835277
[TBL] [Abstract][Full Text] [Related]
18. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
[TBL] [Abstract][Full Text] [Related]
19. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models.
Hodatsu A; Konno T; Hayashi K; Funada A; Fujita T; Nagata Y; Fujino N; Kawashiri MA; Yamagishi M
Am J Physiol Heart Circ Physiol; 2014 Dec; 307(11):H1594-604. PubMed ID: 25281569
[TBL] [Abstract][Full Text] [Related]
20. Ablation of cardiac myosin-binding protein-C accelerates contractile kinetics in engineered cardiac tissue.
de Lange WJ; Grimes AC; Hegge LF; Ralphe JC
J Gen Physiol; 2013 Jan; 141(1):73-84. PubMed ID: 23277475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]